DPI developer Iconovo has announced that Amneal will take over development of a generic version of Symbicort based on Iconovo’s multi-dose ICOres device. Iconovo and Amneal initially signed a licensing and development deal in 2016.
In March 2019, Iconovo had announced that Mumbai-based CBC Corporation would handle development of the DPI. According to the new announcement, “Amneal Ireland Limited will take over all existing obligations of CBC under the current agreement” and “The project will continue according to plan.”
Iconovo CEO Johan Wäborg said, “Iconovo welcomes Amneal as a development partner for our Symbicort project. As we are closing into making larger investments in the project, we feel that Amneal is best positioned to support the project with the required resources and give certainty to the development track. It is a key priority for Iconovo to reach the patients in a timely manner to benefit from the turnover related royalty payments to the company. We look forward to working with Amneal on this exciting project.”
Amneal Co-CEO Chintu Patel commented, “Developing a range of inhalation products remains an important element of Amneal’s portfolio strategy. Amneal expects that combining Iconovo’s extensive experience in inhalation development with Amneal’s capability to bring complex generic medicines to market will set this partnership apart.”
Read the Iconovo press release.
